Waldenstrom Macroglobulinemia: Overview & Treatment Landscape

Created using ChatSlide

This presentation offers a comprehensive overview of Waldenström Macroglobulinemia (WM), beginning with its definition and global significance. It delves into risk stratification using smoldering WM indicators and key biomarkers like IgM and BM LPL. Genomic insights focus on mutations such as MYD88 and CXCR4 and their influence on prognosis. Emerging therapies, including novel BTK and BCL2 inhibitors, as well as CAR-T and CAR-NK therapies, will be explored. The session concludes with...